MARKET

TPST

TPST

Tempest Therapeutics Inc
NASDAQ
3.900
+0.100
+2.63%
After Hours: 3.930 +0.03 +0.77% 19:58 02/23 EST
OPEN
3.710
PREV CLOSE
3.800
HIGH
3.930
LOW
3.680
VOLUME
386.86K
TURNOVER
0
52 WEEK HIGH
9.77
52 WEEK LOW
0.1700
MARKET CAP
75.07M
P/E (TTM)
-1.7450
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TPST last week (0212-0216)?
Weekly Report · 6d ago
Weekly Report: what happened at TPST last week (0205-0209)?
Weekly Report · 02/12 11:47
Jefferies Initiates Coverage On Tempest Therapeutics with Buy Rating, Announces Price Target of $15
Benzinga · 02/08 12:46
Weekly Report: what happened at TPST last week (0129-0202)?
Weekly Report · 02/05 11:58
Tempest Therapeutics Shares Up 19% Premarket. A Press Release Earlier Announced A Presentation On Its Liver Cancer Treatment At ASCO Annual Meeting 2024
Tempest Therapeutics, Inc. Will participate in the American Society of Clinical Oncology Annual Meeting 2024. The company's lead candidate, TPST-1120, is a first-in-class PPARα antagonist for the treatment of liver cancer and other malignancies.
Benzinga · 01/30 11:51
Weekly Report: what happened at TPST last week (0122-0126)?
Weekly Report · 01/29 11:43
Weekly Report: what happened at TPST last week (0115-0119)?
Weekly Report · 01/22 11:49
Weekly Report: what happened at TPST last week (0108-0112)?
Weekly Report · 01/15 11:44
More
About TPST
Tempest Therapeutics, Inc. (Tempest) is a clinical-stage oncology company. The Company is focused on developing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a range of tumors. The Company’s two clinical programs include TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPARa). TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, and is in Phase I monotherapy and combination trials in solid tumors.

Webull offers Tempest Therapeutics Inc stock information, including NASDAQ: TPST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TPST stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TPST stock methods without spending real money on the virtual paper trading platform.